Catalog No.
Product Name
Application
Product Information
Citations
-
IRAK4 Inhibitor
BMS-986126 is a potent and selective inhibitor of IRAK4, with an IC50 value of 5.3 nM. It effectively disrupts MyD88-dependent signaling pathways, thereby attenuating inflammatory responses associated with autoimmune conditions. In preclinical studies, BMS-986126 has demonstrated significant efficacy in murine models of lupus, including MRL/lpr and NZB/NZW strains. This compound is valuable for research applications related to systemic lupus erythematosus (SLE) and other autoimmune diseases. -
IRAK PROTAC Degradant
APH02174 is a highly selective IRAK4 PROTAC degrader that exhibits an impressive DC50 value of 4.01 nM in THP-1 cells. By effectively inhibiting the release of IL-6, APH02174 serves to block inflammatory signaling pathways. This compound is valuable for research into various inflammatory conditions, including psoriasis vulgaris and rheumatoid arthritis. -
c-Met Inhibitor
Tepotinib hydrochloride is a highly selective, reversible, ATP-competitive inhibitor of c-Met, exhibiting an IC50 of 3 nM and over 200-fold selectivity for c-Met compared to other kinases such as IRAK4, TrkA, Axl, IRAK1, and Mer. This compound effectively inhibits c-Met phosphorylation and promotes autophagy. Tepotinib hydrochloride demonstrates significant antitumor activity and is applicable in cancer research targeting c-Met-driven pathways. -
IRAK4 PROTAC Degrader
PROTAC IRAK4 degrader-14 is an orally active degrader targeting IRAK4 with a DC50 of 2.4 nM. It functions by selectively degrading IRAK4, thereby inhibiting pro-inflammatory responses in various cell types, including T cells, monocytes, and keratinocytes. This compound has significant relevance in research focused on inflammatory diseases, particularly psoriasis. -
IRAK4 Inhibitor
UR241-2 is a selective inhibitor of IRAK4, targeting the IL-1–induced IRAK1/4 signaling pathway. It effectively suppresses NF-κB activation and the phosphorylation of p65 and p38, contributing to a reduction in leukemia stem cell clonogenicity. UR241-2 also serves as a valuable ligand for developing PROTAC degraders targeting IRAK4, making it a suitable tool for research in acute myeloid leukemia. -
IRAK4 Inhibitor
Zabedosertib is a selective inhibitor of IRAK4, a protein kinase integral to the signaling pathways of innate immune responses triggered by Toll-like receptors. With an IC50 of 3.55 nM, Zabedosertib demonstrates significant immunomodulatory effects, specifically exhibiting anti-inflammatory activity against IL-1β, lipopolysaccharide (LPS), and Imiquimod-induced inflammation. This compound is suitable for research applications focused on exploring innate immunity and inflammation modulation. -
IRAK1 Inhibitor
JH-X-119-01 is a selective inhibitor of interleukin-1 receptor-associated kinases 1 (IRAK1) that demonstrates significant potential in immunological research. With an IC50 of 9 nM, JH-X-119-01 effectively inhibits IRAK1 activity without affecting IRAK4 at concentrations up to 10 μM. This compound has been shown to mitigate LPS-induced sepsis in animal models, making it a valuable tool for studies focused on inflammation and sepsis-related pathways. -
IRAK-4 Inhibitor
Edecesertib is a selective and potent inhibitor of the interleukin-1 receptor-associated kinase 4 (IRAK-4). It exhibits significant anti-inflammatory activity, making it valuable in the study of inflammatory diseases. Edecesertib is applicable in research focused on rheumatoid arthritis (RA) and lupus erythematosus (LE), contributing to the understanding of therapeutic targets in these conditions. -
IRAK1 Inhibitor
JH-X-119-01 hydrochloride is a selective inhibitor of interleukin-1 receptor-associated kinase 1 (IRAK1), a key player in inflammatory signaling pathways. This compound demonstrates significant potential in reducing LPS-induced sepsis in murine models, indicating its utility in studying inflammatory disorders. Researchers can leverage JH-X-119-01 hydrochloride to explore IRAK1's role in immune responses and develop targeted therapies for sepsis and related conditions. -
IRAK4 Inhibitor
IRAK4-IN-21 is a potent and selective inhibitor of IRAK4, exhibiting IC50 values of 5 nM for IRAK4 and 56 nM for TAK1. This orally active compound effectively inhibits interleukin-23 (IL-23) production with an IC50 of 0.17 μM. IRAK4-IN-21 is valuable for research applications in autoimmune diseases, particularly in the context of plaque psoriasis and psoriatic arthritis. -
IRAK Inhibitor
IRAK4-IN-6 is a selective inhibitor of IRAK4, demonstrating an IC50 of 4 nM. It effectively targets the MyD88 L265P mutant variant associated with diffuse large B cell lymphoma, making it a valuable tool for research in oncology and immune signaling pathways. Its oral efficacy supports in vivo studies, facilitating investigations into IRAK4's role in tumorigenesis and potential therapeutic interventions. -
IRAK4 Inhibitor
IRAK4-IN-22 is a selective IRAK4 inhibitor with potent activity, exhibiting IC50 values of 3 nM for IRAK4 and 17 nM for TAK1. This compound effectively inhibits IL-23 production with an IC50 of 0.10 µM, making it a valuable tool for research into autoimmune conditions such as plaque psoriasis and psoriatic arthritis. Its oral bioavailability enhances its suitability for in vivo studies, facilitating investigations into the therapeutic potential of targeting IRAK4 in inflammatory diseases. -
Bioactive Peptide
IRAK-4 Peptide substrate (IRAK-1 residues 360-380) is a bioactive peptide specifically designed to serve as a substrate for Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4). This peptide facilitates the study of IRAK-4's role in signal transduction pathways associated with inflammatory responses. It is suitable for applications in cellular signaling research, particularly in the context of immune system studies and cytokine signaling. -
IRAK4 Inhibitor
BIO-7488 is a selective IRAK4 inhibitor with a potent IC50 of 0.5 nM, designed to cross the blood-brain barrier effectively. This compound inhibits the production of pro-inflammatory cytokines, including IL-1β, TNFα, and IL-6, displaying significant anti-inflammatory properties in both LPS-induced and distal hypoxic-middle cerebral artery occlusion ischemic stroke models. BIO-7488 is a valuable reagent for researching neuroinflammatory disorders, particularly in the context of ischemic stroke. -
IRAK4 Inhibitor
IRAK4-IN-20 is a potent inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), showcasing an IC50 of 3.55 nM. This compound is indicated for research into inflammatory conditions, particularly acute respiratory distress syndrome (ARDS). Its mechanism of action makes it a valuable tool for studying IRAK4's role in immune signaling pathways and related therapeutic interventions. -
IRAK4 Inhibitor
GLPG2534 is a selective inhibitor of IRAK4, exhibiting IC50 values of 6.4 nM and 3.5 nM for human and mouse IRAK4 respectively. This compound effectively modulates inflammatory signaling pathways involved in immune responses. GLPG2534 is suitable for research aimed at understanding and developing treatments for inflammatory skin diseases. -
PROTAC IRAK4 Degrader
PROTAC IRAK4 Degrader-3 is a PROTAC-based ligand designed to target and induce the degradation of interleukin-1 receptor-associated kinase 4 (IRAK4) via the von Hippel-Lindau (VHL) E3 ubiquitin ligase. This compound effectively modulates the inflammatory response by selectively degrading IRAK4, making it a valuable tool for exploring therapeutic strategies in inflammatory diseases and immune signaling pathways. Its application in research can provide insights into IRAK4's role in various pathologies, including cancer and autoimmune disorders. -
PROTAC IRAK4 Degrader
PROTAC IRAK4 Degrader-8 is a targeted protein degradation compound designed to selectively degrade IRAK4, demonstrating an IC50 of 15.5 nM. This reagent effectively induces IRAK4 degradation in THP-1 cells with a DC50 of 1.8 nM. Additionally, PROTAC IRAK4 Degrader-8 inhibits L-6 production in human whole blood and LPS-induced human peripheral blood mononuclear cells, exhibiting IC50 values of 246 nM and 2.2 nM, respectively. This compound is a valuable tool for studying the role of IRAK4 in immune responses and offers potential applications in inflammatory and autoimmune research. -
IRAK4 Inhibitor
IRAK4-IN-14 is a potent, selective inhibitor of IRAK4, demonstrating an IC50 of 0.003 µM. This orally active compound exhibits favorable pharmacokinetic properties in both rat and mouse models. IRAK4-IN-14 has shown synergy in vitro against MyD88/CD79 double mutant ABC-DLBCL when used in combination with Acalabrutinib, making it a valuable tool for research in oncology and inflammation pathways. -
IRAK4 Inhibitor
PF-06426779 is a potent and selective inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4), displaying an IC50 of 0.3 nM. This compound effectively modulates inflammatory signaling pathways and is useful in the study of diseases related to dysregulated immune responses. Researchers can leverage PF-06426779 in experimental settings exploring the roles of IRAK4 in cellular processes and potential therapeutic interventions in inflammation-driven disorders. -
IRAK-4 Inhibitor
IRAK-4 protein kinase inhibitor 2 selectively targets interleukin-1 receptor-associated kinase-4 (IRAK-4) with an IC50 of 4 μM. This inhibitor is instrumental in studying inflammatory and immune-related diseases, offering valuable insights into the mechanisms underlying these conditions. Its effective application in research may lead to better understanding and potential therapeutic developments in immune responses. -
IRAK4 Inhibitor
HS271 is a selective inhibitor of IRAK4, demonstrating potent activity with an IC50 of 7.2 μM. This compound exhibits superior enzymatic and cellular efficacy, making it suitable for studies investigating IRAK4-mediated signaling pathways. HS271’s excellent pharmacokinetic properties further enhance its utility in various biological research applications focused on inflammatory processes and immune response modulation. -
IRAK4 Inhibitor
GNE-2256 is a potent inhibitor of IRAK4 (Interleukin 1 receptor associated kinase 4) with a Ki of 1.4 nM, demonstrating high selectivity for this target. It effectively reduces IL-6 production with an IC50 of 190 nM, making it a valuable tool for investigating inflammatory responses and signaling pathways. GNE-2256 is suitable for studies involving autoimmune diseases and other conditions related to aberrant IL-6 signaling. -
IRAK Inhibitor
IRAK inhibitor 4 (trans) is a selective inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). This compound has demonstrated significant efficacy in blocking IRAK4 activation, thereby modulating the downstream signaling pathways involved in inflammatory responses. It is widely used in research applications focusing on inflammatory disorders and signaling pathways associated with innate immunity. -
IRAK4 Inhibitor
IRAK4-IN-8 is a potent inhibitor of IRAK4, an essential kinase in the interleukin-1 receptor (IL-1R) and Toll-like receptor (TLR) signaling pathways. By selectively inhibiting IRAK4, it modulates downstream inflammatory responses, making it a valuable tool for studying immune pathways. Its primary applications include research on autoimmune disorders, cancer immunotherapy, and the development of novel anti-inflammatory drugs. -
IRAK4 Inhibitor
IRAK4-IN-18 is a selective inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), exhibiting an IC50 value of 15 nM. This compound is effective in inhibiting lipopolysaccharide (LPS)-induced interleukin-23 (IL-23) production in THP-1 and dendritic cells, demonstrating its potential to modulate inflammatory responses. IRAK4-IN-18 is applicable for research into arthritis and related inflammatory diseases. -
IRAK1/4/pan-FLT3 Inhibitor
IRAK1/4/pan-FLT3 Kinase-IN-2 is a dual inhibitor targeting IRAK1, IRAK4, and FLT3 with IC50 values of 10 nM, 0.7 nM, and <0.5 nM, respectively. This compound demonstrates significant biological activity by extending survival in acute myeloid leukemia model mice. It serves as a valuable tool for research in hematological malignancies and associated therapeutic pathways, facilitating studies on the modulation of kinase activity in cancer. -
PROTAC IRAK4 Degrader
PROTAC IRAK4 Degrader-5 is a Cereblon-based targeted protein degrader specifically designed to induce the degradation of IRAK4. By modulating the ubiquitin-proteasome system, it enhances protein turnover, leading to a decrease in IRAK4 levels. This compound is valuable for research applications focused on inflammation and immune response regulation, enabling the investigation of IRAK4's role in various disease models. -
IRAK4 Inhibitor
IRAK4-IN-16 is a potent inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4), displaying an IC50 value of 2.5 nM. This compound demonstrates significant cytotoxic effects against various lymphoma cell lines, including OCI-LY10, TMD8, Ramos, and HT, with respective IC50 values of 0.2 μM, 0.2 μM, 0.6 μM, and 2.7 μM. IRAK4-IN-16 is valuable for research in the mechanisms of inflammation and cancer therapy, particularly in targeting IRAK4-related pathways. -
Ligand for Target Protein for PROTAC
PROTAC IRAK4 ligand-4 is a selective ligand that targets IRAK4, facilitating the degradation of this protein via the PROTAC (proteolysis-targeting chimera) mechanism. This compound exhibits antitumor activity, making it a valuable tool for cancer research. Additionally, it can be utilized to synthesize the PROTAC IRAK4 degrader-12, contributing to the development of targeted therapeutic strategies in oncology. -
PROTAC IRAK4 Degrader
PROTAC IRAK4 degrader-12 is a PROTAC compound designed to selectively target and induce the degradation of IRAK4 via the Cereblon E3 ligase pathway. It demonstrates a significant degradation efficacy, achieving a maximum degradation rate of 108.46% in K562 cells with an IC50 of 4.87 nM. This reagent is particularly useful for research applications focused on inflammatory signaling pathways and therapeutic development targeting IRAK4-related diseases. -
IRAK4 Inhibitor
IRAK4-IN-9 is a potent inhibitor of IRAK4, demonstrating an IC50 of 1.5 nM. This compound effectively disrupts MyD88-dependent signaling pathways, making it a valuable tool for investigating mechanisms of inflammation and immune response. IRAK4-IN-9 is relevant for research applications in inflammatory diseases, autoimmune disorders, and cancer biology. -
IRAK4 Inhibitor
IRAK4-IN-10 is a potent inhibitor of IRAK4, exhibiting an IC50 value of 1.5 nM. This compound effectively interrupts MyD88-dependent signaling pathways, making it a valuable tool for studying the molecular mechanisms underlying inflammatory and autoimmune diseases, as well as various cancers. Its ability to target IRAK4 positions IRAK4-IN-10 as a promising reagent for research in related therapeutic fields. -
IRAK4 Inhibitor
IRAK4-IN-13 is a potent and selective inhibitor of IRAK4 with an IC50 of 0.6 nM. This compound demonstrates significant metabolic clearance, with an intrinsic clearance rate of 96 µL/min/mg in human liver microsomes. IRAK4-IN-13 is useful for studying IRAK4-mediated signaling pathways and evaluating therapeutic strategies in various inflammatory diseases. -
IRAK4 Inhibitor
IRAK4-IN-31 is a selective inhibitor of IRAK4, a key kinase in the Toll-like receptor signaling pathway. This compound exhibits potent inhibitory activity against IRAK4, making it valuable for studying immune signaling and associated pathways. IRAK4-IN-31 is particularly relevant in research related to myelodysplastic syndromes (MDS) and may aid in elucidating therapeutic strategies for hematological malignancies. -
IRAK4 Modulator
IRAK4 modulator-1 is a selective modulator of IRAK4, demonstrating an IC50 of 4.647 μM. This compound is instrumental in the exploration of IRAK-mediated signaling pathways, making it a valuable tool for investigating diseases associated with dysregulated inflammation and immune responses. Researchers can utilize IRAK4 modulator-1 to further understand the role of IRAK4 in various pathological conditions. -
IRAK3 PROTAC Degrader
PROTAC IRAK3 degrader-2 is a potent IRAK3 PROTAC degrader with a DC50 of less than or equal to 50 nM. This compound promotes the ubiquitination and subsequent degradation of the IRAK3 protein, making it a valuable tool for studying immune-related diseases. Its unique design incorporates ligands for E3 ligase and a linker configuration, facilitating targeted degradation and aiding research into therapeutic strategies for modulating immune responses. -
IRAK4 Inhibitor
DW18134 is a selective inhibitor of interleukin receptor-associated kinase 4 (IRAK4) with an IC50 of 11.2 nM. It effectively inhibits the phosphorylation of IRAK4 and IKK, leading to downregulated secretion of pro-inflammatory cytokines TNF-α and IL-6. In preclinical studies, DW18134 demonstrates efficacy in mitigating lipopolysaccharide-induced peritonitis and dextran sulfate sodium-induced colitis in mouse models, while also preserving intestinal barrier integrity. This compound is valuable for researching inflammatory pathways and therapeutic strategies in inflammatory bowel disease. -
PROTAC IRAK4 Degrader
PROTAC IRAK4 Degrader-2 is a PROTAC-based compound designed to target and degrade IRAK4, displaying potent degradation efficacy with a DC50 value of 151 nM in peripheral blood mononuclear cells (PBMCs). It effectively reduces IRAK4 protein levels, achieving a DC50 of 36 nM in these cells. Additionally, PROTAC IRAK4 Degrader-2 inhibits the production of multiple cytokines, making it a valuable tool for research in inflammation and immune response modulation. -
PROTAC IRAK4 Degrader
KTX-612 is an orally bioavailable IRAK4 PROTAC degrader with a DC50 value of 7 nM. This compound is designed to selectively target and promote the degradation of IRAK4, a key protein involved in inflammatory and oncogenic signaling pathways. KTX-612 has potential applications in oncology research, facilitating studies focused on the modulation of IRAK4 and its implications in cancer progression and treatment. -
IRAK4 ligand
IRAK4 ligand-13 is a selective ligand targeting IRAK4, a key component in the interleukin-1 receptor and Toll-like receptor signaling pathways. This compound is designed for the development of proteolysis-targeting chimeras (PROTACs), facilitating targeted protein degradation. It is suitable for research applications aimed at modulating immune responses and studying signaling pathways associated with inflammation and cancer. -
IRAK4 Inhibitor
BIO-8169 is a selective inhibitor of interleukin receptor-associated kinase 4 (IRAK4) with an IC50 of 0.23 nM. This compound demonstrates significant anti-inflammatory activity by reducing the production of pro-inflammatory cytokines. Additionally, BIO-8169 shows promising pharmacokinetic properties, including effective blood-brain barrier penetration, indicated by a rat Kpu,u of 0.7, making it suitable for investigating autoimmune conditions such as experimental autoimmune encephalomyelitis (EAE). -
IRAK3 Degrader PROTAC
PROTAC IRAK3 degrader-1 is a potent and selective degrader targeting IRAK3, with an IC50 of 5 nM. This compound effectively facilitates the ubiquitination and subsequent degradation of IRAK3, thereby modulating inflammatory responses. Its primary research applications include studies on innate immunity and the development of targeted therapies for inflammatory diseases. -
PROTAC IRAK4 Degrader
PROTAC IRAK4 degrader-4 is a Cereblon-based bifunctional molecule designed to degrade interleukin-1 receptor-associated kinase 4 (IRAK4). This compound facilitates targeted protein degradation, leading to effective modulation of IRAK4 levels in cells. Research applications include investigating inflammatory signaling pathways and therapeutic approaches for autoimmune diseases. -
PROTAC IRAK4 Degrader
KTX-497 is a potent IRAK4 degrader utilizing the PROTAC technology, exhibiting a DC50 value of 3 nM. This compound effectively targets and degrades IRAK4, making it a valuable tool for oncology research. Its mechanism allows for the selective modulation of signaling pathways implicated in cancer progression, facilitating the exploration of novel therapeutic strategies. -
PROTAC IRAK4 Degrader
KTX-955 is a potent IRAK4 degrader that facilitates the targeted degradation of IRAK4 protein. With DC50 values of 5 nM for IRAK4 and 130 nM for Ikaros, this compound demonstrates significant efficacy in modulating signaling pathways involved in tumorigenesis. KTX-955 comprises a CRBN ligand derived from Pomalidomide and a specific ligand targeting IRAK4, making it a valuable tool for research into cancer biology and therapeutic interventions. -
IRAK4 Inhibitor
IRAK4-IN-28 is a potent inhibitor of IRAK4, exhibiting an IC50 of 8.9 nM and a binding affinity characterized by a Kd of 0.58 nM. This compound is suitable for studies targeting inflammation and autoimmune diseases, providing valuable insights into the mechanisms of immune response modulation. Its selectivity and potency make it a useful tool for elucidating the role of IRAK4 in various biological processes. -
IRAK4 Inhibitor
IRAK4-IN-15 is a selective inhibitor of IRAK4, demonstrating a remarkable IC50 of 0.002 µM. This compound exhibits favorable pharmacokinetic predictions in humans with low intrinsic clearance. In vitro studies reveal its potent synergistic activity against MyD88/CD79 double mutant ABC-DLBCL, particularly when used in combination with Acalabrutinib, positioning IRAK4-IN-15 as a valuable tool in cancer research. -
IRAK4 Inhibitor
IRAK4-IN-30 is a potent inhibitor of IRAK4, with an IC50 of 0.6 nM. This compound effectively modulates the signaling pathways associated with the innate immune response. It is valuable for research applications focused on inflammation, autoimmunity, and cancer, providing insights into the mechanistic roles of IRAK4 in various biological processes. -
IRAK4 Inhibitor
IRAK4-IN-17 is a potent inhibitor of IRAK4, exhibiting an IC50 of 1.3 nM. This compound is instrumental for research involving diffuse large B-cell lymphoma (DLBCL), providing insight into the role of IRAK4 in oncogenic signaling pathways. Its high specificity and efficacy make it a valuable tool for investigating therapeutic strategies targeting IRAK4-related mechanisms in cancer biology.
